USFDA Inspection Of Granules' Visakhapatnam Unit Concludes With Zero Observations

Granules India’s active pharmaceutical ingredients (API) manufacturing facility in Visakhapatnam, Andhra Pradesh, has completed a U.S. Food and Drug Administration (U.S. FDA) inspection, the company said on Friday.

The Unit IV facility located in Visakhapatnam has successfully completed the U.S. FDA’s pre-approval inspection and GMP audit from June 26-30 with zero [Form 483] observations, the company said.

It also said in the filing that its facility at Jeedimetla (Hyderabad) also completed the US FDA’s surveillance inspection.

From June 26, 2023, through June 30, 2023, there was an audit. The company stated in an exchange filing that the Unit IV plant in Visakhapatnam produces active medicinal ingredients.

Source: Media reports

Top stories
Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read . 02 Aug 2024 . 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read . 02 Aug 2024 . 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read . 02 Aug 2024 . 12:36 PM

Related Blogs
blog-logo

Share Market

blog-logo

9 mins read . 11 Oct 2024

Public Sector Undertakings in India

  • 0 people read
blog-logo

Share Market

blog-logo

7 mins read . 11 Oct 2024

How Did Rakesh Jhunjhunwala Become a Billionaire?

  • 0 people read
Kickstart your equities journey today You've got this
By submitting this I agree to the terms & conditions